Page 84 - Read Online

Page 28 of 29 Aguiar. Rare Dis Orphan Drugs J 2024;3:13 https://dx.doi.org/10.20517/rdodj.2023.56

Inherit Metab Dis 2012;35:363-7. DOI PubMed
216. Lelieveld IM, Böttcher A, Hennermann JB, Beck M, Fellgiebel A. Eight-year follow-up of neuropsychiatric symptoms and brain
structural changes in Fabry disease. PLoS One 2015;10:e0137603. DOI PubMed PMC
217. Segura T, Ayo-Martín O, Gómez-Fernandez I, Andrés C, Barba MA, Vivancos J. Cerebral hemodynamics and endothelial function in
patients with Fabry disease. BMC Neurol 2013;13:170. DOI PubMed PMC
218. Domon B, Aebersold R. Challenges and opportunities in proteomics data analysis. Mol Cell Proteomics 2006;5:1921-6. DOI
PubMed
219. Matthews H, Hanison J, Nirmalan N. “Omics”-informed drug and biomarker discovery: opportunities, challenges and future
perspectives. Proteomes 2016;4:28. DOI PubMed PMC
220. Betzen C, Alhamdani MS, Lueong S, Schröder C, Stang A, Hoheisel JD. Clinical proteomics: promises, challenges and limitations of
affinity arrays. Proteomics Clin Appl 2015;9:342-7. DOI PubMed PMC
221. Dupont FO, Gagnon R, Boutin M, Auray-Blais C. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease
biomarkers. Curr Med Chem 2013;20:280-8. DOI PubMed
222. Manwaring V, Boutin M, Auray-Blais C. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the
plasma of Fabry disease patients. Anal Chem 2013;85:9039-48. DOI PubMed
223. Boutin M, Auray-Blais C. Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers. J Am
Soc Mass Spectrom 2015;26:499-510. DOI PubMed
224. Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT. Urinary globotriaosylsphingosine-related biomarkers for
Fabry disease targeted by metabolomics. Anal Chem 2012;84:2745-53. DOI PubMed
225. Lavoie P, Boutin M, Abaoui M, Auray-Blais C. Fabry disease biomarkers: analysis of urinary lyso-Gb3 and seven related analogs
using tandem mass spectrometry. Curr Protoc Hum Genet 2016;90:17.22.1-12. DOI PubMed
226. Cuccurullo M, Beneduci A, Anand S, et al. Fabry disease: perspectives of urinary proteomics. J Nephrol 2010;23:S199-212. PubMed
227. Kistler AD, Siwy J, Breunig F, et al. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response
to enzyme replacement therapy. PLoS One 2011;6:e20534. DOI PubMed PMC
228. Manwaring V, Heywood WE, Clayton R, et al. The identification of new biomarkers for identifying and monitoring kidney disease
and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and
type-I diabetic patients. J Proteome Res 2013;12:2013-21. DOI
229. Matafora V, Cuccurullo M, Beneduci A, et al. Early markers of Fabry disease revealed by proteomics. Mol Biosyst 2015;11:1543-51.
DOI
230. Vojtová L, Zima T, Tesař V, et al. Study of urinary proteomes in Anderson-Fabry disease. Ren Fail 2010;32:1202-9. DOI
231. Doykov ID, Heywood WE, Nikolaenko V, et al. Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry
disease. J Med Genet 2020;57:38-47. DOI
232. Altarescu G, Chicco G, Whybra C, et al. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms
and CRP levels with the mainz severity score index for Fabry disease. J Inherit Metab Dis 2008;31:117-23. DOI
233. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous
males with Fabry disease. Neurology 2006;67:2045-7. DOI PubMed PMC
234. Vedder AC, Biró E, Aerts JM, Nieuwland R, Sturk G, Hollak CE. Plasma markers of coagulation and endothelial activation in Fabry
disease: impact of renal impairment. Nephrol Dial Transplant 2009;24:3074-81. DOI PubMed
235. Yogasundaram H, Nikhanj A, Putko BN, et al. Elevated inflammatory plasma biomarkers in patients with fabry disease: a critical link
to heart failure with preserved ejection fraction. J Am Heart Assoc 2018;7:e009098. DOI PubMed PMC
236. Chen KH, Chien Y, Wang KL, et al. Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme
replacement therapy. Can J Cardiol 2016;32:1221.e1-9. DOI
237. Chien Y, Chien CS, Chiang HC, et al. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left
ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget 2016;7:87161-79. DOI PubMed PMC
238. Vedder AC, Cox-Brinkman J, Hollak CE, et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden
macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 2006;89:239-44. DOI
239. Degraba T, Azhar S, Dignat-george F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol
2000;47:229-33. PubMed
240. Fedi S, Gensini F, Gori AM, Abbate R, Borsini W. Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's
disease. J Thromb Haemost 2005;3:2117-9. DOI PubMed
241. Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl
2002;91:57-61. DOI PubMed
242. Rohard I, Schaefer E, Kampmann C, Beck M, Gal A. Association between polymorphisms of endothelial nitric oxide synthase gene (
NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease. J Inherit Metab Dis 2008;31:S349-56. DOI PubMed
243. Loso J, Lund N, Avanesov M, et al. Serum biomarkers of endothelial dysfunction in Fabry associated cardiomyopathy. Front
Cardiovasc Med 2018;5:108. DOI PubMed PMC
244. Brakch N, Dormond O, Bekri S, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.
Eur Heart J 2010;31:67-76. DOI
245. Aguiar P, Azevedo O, Pinto R, et al. Biomarkers of myocardial fibrosis: revealing the natural history of fibrogenesis in Fabry disease